| Bioactivity | Menin-MLL inhibitor 29 (Compound C1) is a Menin-MLL PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a KD value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC50 value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC50s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth[1]. |
| Target | Menin-MLL PPI |
| Name | Menin-MLL inhibitor 29 |
| Formula | C36H26Br2F6N4PRh |
| Molar Mass | 922.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhong HJ, et al. Development of an orally bioavailable selective inhibitor of the menin-MLL. Genes Dis. 2022 Oct 18;10(5):1735-1738. |
Menin-MLL inhibitor 29
CAS: F: C36H26Br2F6N4PRh W: 922.30
Menin-MLL inhibitor 29 (Compound C1) is a Menin-MLL PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a KD value
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.